SCHEMBL2052884

SCHEMBL2052884

C=CCC(N)(CC=C)CCN

nearest known ligand 0.35

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL27780274 0.97 ALDH1A1 (0.33) ALDH1A1
Phosphoric Acid SCHEMBL27779615 0.87 FDPS (0.40) ALDH1A1
SCHEMBL17303184 0.84 ALDH1A1 (0.32) ALDH1A1
SCHEMBL8606468 0.82 NFKB1 (0.33) ALDH1A1
SCHEMBL10618555 0.80 CA12 (0.36) ALDH1A1
SCHEMBL627289 0.80
SCHEMBL627290 0.80
SCHEMBL361077 0.78 ALDH1A1 (0.38) ALDH1A1
SCHEMBL361436 0.78 TSHR (0.30)
SCHEMBL368093 0.77 ALDH1A1 (0.39) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230405043-A1 PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION RENIBUS THERAPEUTICS, INC. 2023-12-21 US claimed
US-20190134076-A1 HCL-BINDING COMPOSITIONS FOR AND METHODS OF TREATING ACID-BASE DISORDERS RENIBUS THERAPEUTICS, INC. 2019-05-09 US claimed
WO-2017193024-A9 HCL-BINDING COMPOSITIONS FOR AND METHOD OF TREATING ACID-BASE DISORDERS TRICIDA, INC. (US) 2018-11-22 WO claimed
US-9993500-B2 Proton-binding polymers for oral administration TRICIDA, INC. (US) 2018-06-12 US claimed
US-20180021370-A1 PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION RENIBUS THERAPEUTICS, INC. 2018-01-25 US claimed
WO-2017193024-A1 HCL-BINDING COMPOSITIONS FOR AND METHOD OF TREATING ACID-BASE DISORDERS TRICIDA, INC. (US) 2017-11-09 WO claimed
EP-3229816-A1 PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION Tricida Inc. (US) 2017-10-18 EP claimed
WO-2016094685-A1 PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION TRICIDA, INC. (US) 2016-06-16 WO claimed
US-9205107-B2 Proton-binding polymers for oral administration TRICIDA, INC. (US) 2015-12-08 US claimed
US-11992501-B2 Compositions for and methods of treating acid-base disorders RENOSIS, INC. (US) 2024-05-28 US disclosed
US-11986490-B2 Compositions for and method of treating acid-base disorders RENOSIS, INC. (US) 2024-05-21 US disclosed
US-20230405043-A1 PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION RENIBUS THERAPEUTICS, INC. 2023-12-21 US disclosed
US-11738041-B2 Proton-binding polymers for oral administration RENOSIS, INC. (US) 2023-08-29 US disclosed
CN-109414453-B Composition for treating acid-base imbalance 特里赛达公司 2023-02-17 CN disclosed
WO-2000046274-A1 PROCESS FOR THE MANUFACTURE OF FUNCTIONALIZED POLYPHENYLENE ETHERS GENERAL ELECTRIC COMPANY (US) 2000-08-10 WO disclosed
US-6096891-A Process for the production of cyclic N,N'-dialkylureas AIR PRODUCTS AND CHEMICALS, INC. (US) 2000-08-01 US disclosed
EP-0307775-B1 Water dispersible, modified polyurethane thickener with improved high shear viscosity in aqueous systems RHEOX INT (US) 1993-11-03 EP disclosed
US-5023309-A Polyetherurethane copolymer modified by a hydrophobic agent and a end group; resistant to microbiocides; good sag and leveling properties; paints; coatings RHEOX, INC. (US) 1991-06-11 US disclosed
WO-1989002451-A1 WATER DISPERSIBLE, MODIFIED POLYURETHANE THICKENER WITH IMPROVED HIGH SHEAR VISCOSITY IN AQUEOUS SYSTEMS NL CHEMICALS, INC. (US) 1989-03-23 WO disclosed
EP-0307775-A2 Water dispersible, modified polyurethane thickener with improved high shear viscosity in aqueous systems RHEOX INTERNATIONAL, INC. (US) 1989-03-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11992501-B2 Compositions for and methods of treating acid-base disorders SLC10A2, SLC10A1, SLC26A3 ALDH1A1 1554/4885
US-20190134076-A1 HCL-BINDING COMPOSITIONS FOR AND METHODS OF TREATING ACID-BASE DISORDERS SLC10A2, SLC10A1, SLC7A1 ALDH1A1 1901/4885
US-20180021370-A1 PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION SLC9A1, HRH2, SLC9A2 ALDH1A1 3400/4885
US-11738041-B2 Proton-binding polymers for oral administration SLC9A1, HRH2, SLC9A2 ALDH1A1 3400/4885
US-20230405043-A1 PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION SLC9A1, HRH2, SLC9A2 ALDH1A1 3400/4885
US-11986490-B2 Compositions for and method of treating acid-base disorders SLC10A2, SLC10A1, GLS ALDH1A1 773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.